(E)-4-(3-chloroprop-1-en-1-yl)-1,2-dimethoxybenzene | 207272-37-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-4-(3-chloroprop-1-en-1-yl)-1,2-dimethoxybenzene
• 英文别名: 4-[(1E)-3-chloroprop-1-en-1-yl]-1,2-dimethoxybenzene；4-[(E)-3-chloroprop-1-enyl]-1,2-dimethoxybenzene
• CAS: 207272-37-5
• 化学式: C₁₁H₁₃ClO₂
• 分子量: 212.676
• InChiKey: XPPDIDRILNIYOL-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-4-(3-chloroprop-1-en-1-yl)-1,2-dimethoxybenzene 在 sodium ethanolate 、 N,N-二乙基苯胺 作用下， 反应 37.0h， 生成 (2S,3S)-2-(3,4-二甲氧基苯基)-7-甲氧基-3-甲基-2,3-二氢-1-苯并呋喃-5-甲醛
  参考文献：
  名称：

  (±)-Kadsurenin M† 的全合成

  摘要：

  外消旋 kadsurenin M 的首次全合成以香草醛为原料，通过关键中间体 3,4-二甲氧基肉桂基 4-甲酰基-2-甲氧基苯基醚完成。

  DOI：

  10.1039/a706443h
• 作为产物：
  描述：

  ethyl (E)-3,4-dimethoxycinnamate 在 磺酰氯 、 二异丁基氢化铝 作用下， 以 乙醚 、 二氯甲烷 、 环己烷 为溶剂， 反应 4.0h， 生成 (E)-4-(3-chloroprop-1-en-1-yl)-1,2-dimethoxybenzene
  参考文献：
  名称：

  1,7-Enynes的发散金（I）催化的骨骼重排

  摘要：

  金（I）配合物催化的1，n炔烃（n = 5-7）的环异构化和骨架重排是有效合成复杂分子结构的有力方法。与1,6-烯炔相反，在这种转化中，基本上没有探索到容易获得的同源1,7-烯炔。在此，据报道，通过阳离子金（I）络合物的催化作用，全碳1,7-烯炔的骨架发生了不同的重排。根据电子和位阻因素，不同取代的1,7-烯炔通过普通金卡宾中间体形成的不同碳正离子反应，一方面通过新型脱氢Diels-Alder生成新型环外亚芳基，另一方面生成三环六氢蒽。反应。

  DOI：

  10.1002/chem.201502843

文献信息

• Nitrosated and nitrosylated compounds, compositions and methods use
  申请人：Earl A. Richard

  公开号：US20060009431A1

  公开（公告）日：2006-01-12

  The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and at least one nitric oxide donor compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering at least one compound of the invention that is optionally nitrosated and/or nitrosylated, in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The compounds of the invention are preferably estradiol compounds, troglitazone compounds, tranilast compounds, retinoic acid compounds, resveratol compounds, myophenolic acid compounds, acid compounds, anthracenone compounds and trapidil compounds.

  该发明描述了该发明的新型亚硝酰化和/或亚硝基化化合物及其药学上可接受的盐，并且描述了包含至少一种该发明的亚硝酰化和/或亚硝基化化合物的新型组合物，以及可选地包含至少一种一氧化氮供体化合物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种该发明化合物的新型组合物，该化合物可选地亚硝酰化和/或亚硝基化，以及至少一种一氧化氮供体化合物和/或至少一种治疗剂。该发明的化合物和组合物也可以与基质结合。该发明还提供了治疗心血管疾病、抑制血液暴露于医疗设备导致的血小板聚集和粘附、治疗由异常细胞增殖引起的病理性状况；移植排斥、自身免疫、炎症、增殖、过度增殖或血管疾病；减少瘢痕组织或抑制伤口收缩，特别是通过在生理条件下给予至少一种可选地亚硝酰化和/或亚硝基化的该发明化合物与能够释放一氧化氮或在生理条件下间接传递或传递一氧化氮到靶位点的一氧化氮供体的组合物来预防和/或治疗再狭窄的预防性和/或治疗性治疗的方法。该发明的化合物首选为雌二醇化合物、曲格列酮化合物、曲安奈德化合物、视黄酸化合物、白藜芦醇化合物、肌酚酸化合物、酸化合物、蒽酮化合物和曲唑酮化合物。
• EC18 as a Tool To Understand the Role of HCN4 Channels in Mediating Hyperpolarization-Activated Current in Tissues
  作者：Maria Novella Romanelli、Martina Del Lungo、Luca Guandalini、Mehrnoush Zobeiri、András Gyökeres、Tamás Árpádffy-Lovas、Istvan Koncz、Laura Sartiani、Gianluca Bartolucci、Silvia Dei、Dina Manetti、Elisabetta Teodori、Thomas Budde、Elisabetta Cerbai

  DOI：10.1021/acsmedchemlett.8b00587

  日期：2019.4.11

  Hyperpolarization-activated cyclic nucleotidegated (HCN) channels are membrane proteins encoded by four genes (HCN1-4) and widely distributed in the central and peripheral nervous system and in the heart. HCN channels are involved in several physiological functions, including the generation of rhythmic activity, and are considered important drug targets if compounds with isoform selectivity are developed. At present, however, few compounds are known, which are able to discriminate among HCN channel isoforms. The inclusion of the three-methylene chain of zatebradine into a cyclohexane ring gave a compound (3a) showing a 5-fold preference for HCN4 channels, and ability to selectively modulate Ih in different tissues. Compound 3a has been tested for its ability to reduce II, and to interact with other ion channels in the heart and the central nervous system. Its preference for HCN4 channels makes this compound useful to elucidate the contribution of this isoform in the physiological and pathological processes involving hyperpolarization-activated
• METHOD FOR PRODUCING PRIMARY AMINE COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1967509B1

  公开（公告）日：2010-04-14
• Process for preparation of rooperol, hypoxoside and derivatives thereof
  申请人：ROOPEROL (NA) NV

  公开号：EP0206765B1

  公开（公告）日：1991-03-06
• Compounds having peripheral calcium antagonist, anticonvulsive and eumetabolic activity, processes for the preparation thereof and pharmaceutical compositions containing them
  申请人：PULITZER ITALIANA S.p.A.

  公开号：EP0152799B1

  公开（公告）日：1987-10-28